Affimed has built a portfolio of novel therapeutic antibodies, based on the unique TandAb® platform, representing a potent alternative to existing IgG-based therapies.
Affimed is preparing to enter partnering deals and strategic alliances around its proprietary product candidates and its TandAb® technology platform.
RECRUIT-TandAbs® represent a unique and potent alternative to therapeutic monoclonal antibodies in oncology. They possess an enhanced killing potency and an excellent safety profile. As compared to other fragment-based technologies, the long half-life of TandAbs® allows convenient dosing schedules.
The PROLONG-TandAb® and BiBLOCK-TandAb® platform enables a multiple target approach with enhanced phasrmacokinetics.
Based on its proprietary TandAb® technology platform, Affimed has generated a portfolio of innovative therapeutic antibody formats targeting attractive indications with high medical need. Our product candidates were selected against targets for which products are on the market or in advanced clinical development, such as CD19, CD30, CD3, EpCAM and others.
Affimed plans to form partnerships based on its proprietary TandAb platform and its product portfolio. Affimed’s capabilities cover all steps from early discovery to clinical proof of concept. There are several options for a collaboration:
- Reengineering of existing antibodies into TandAbs.
- Generation of TandAbs based on Affimed’s more than 10 existing antibody candidates.
- De novo screening of TandAbs against new targets starting from fully human antibody libraries.
- Product related partnerships based on its pre-clinical and clinical pipeline.